Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved by the FDA for the treatment of type 2 diabetes, they have since also transformed the therapeutic landscape of obesity and weight management. These medications are clearly effective. They stimulate the release of insulin and … Read more
An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing mortality gap faced by people with serious mental illnesses by tackling cardiovascular risk and metabolic disease head-on. Editorial: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder … Read more
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by UCL researchers. The world’s largest and longest trial of exenatide in people with Parkinson’s disease was funded by the National Institute for Health & Care Research (NIHR) with support for … Read more